Pemrametostat

DB19170InvestigationalSmall molecule

Pemrametostat is under investigation in clinical trial NCT03614728 (Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia...

Mechanism: Pharmacologically active on Protein arginine N-methyltransferase 5
Curator reviewed
Formula / weight: C₂₄H₃₂N₆O₃ · 452.559 g/mol (avg)
Also known as: 4-pyrimidinecarboxamide, 6-((1-acetyl-4-piperidinyl)amino)-n-((2s)-3-(3,4-dihydro-2(1h)-isoquinolinyl)-2-hydroxypropyl)- · 6-((1-acetyl-4-piperidinyl)amino)-n-((2s)-3-(3,4-dihydro-2(1h)-isoquinolinyl)-2-hydroxypropyl)-4-pyrimidinecarboxamide · Protein arginine methyltransferase 5 inhibitor gsk3326595
Code names: EPZ-015938 · GSK-3326595

Resolves to

Compound

UNIIVXT8SZ6875CAS1616392-22-3ChEMBLCHEMBL4466233

Structure

InChIKeyJLCCNYVTIWRPIZ-NRFANRHFSA-NSMILESCC(=O)N1CCC(CC1)NC1=CC(=NC=N1)C(=O)NC[C@H](O)CN1CCC2=CC=CC=C2C1

Targets

O14744PRMT5

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pemrametostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account